Article Text

PDF
A pilot study on changes of macrophage colony stimulating factor and transforming growth factor β1 in male patients with ankylosing spondylitis taking thalidomide
  1. PT Yang1,
  2. WG Xiao1,
  3. L Qin2,
  4. LJ Zhao1,
  5. LM He3,
  6. M Ito3
  1. 1Department of Rheumatology and Immunology, First Affiliated Hospital, China Medical University, Shenyang, China
  2. 2Department of Physiology, China Medical University, Shenyang, China
  3. 3Department of Microbiology, University of Yamanashi, Yamanashi, Japan
  1. Correspondence to Dr Pingting Yang, Department of Rheumatology and Immunology, First Affiliated Hospital, China Medical University, 155 North Nanjing Street, Shenyang, Liaoning 110001, China; yangpingting{at}yahoo.com

Statistics from Altmetric.com

Ankylosing spondylitis (AS) is a progressive disease of which spinal fusion is the clinical and pathological hallmark. Thalidomide has some efficacy in treating axial inflammation in AS.1 Here, we report clinical responses and changes of serum macrophage colony stimulating factor (M-CSF) and transforming growth factor β1 (TGFβ1) in Chinese male patients with active AS taking thalidomide.

This study enrolled 29 male patients with active AS, whose Bath ankylosing spondylitis disease activity index (BASDAI) was 3 or above.2 A total of 16 patients not intending to have children within the next 2 years took thalidomide (75 mg every night postoperatively) and diclofenac sodium (50 mg 3 times a day postoperatively) for 12 weeks; other patients took diclofenac sodium (50 mg 3 times a day postoperatively) alone. There were no …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.